- Company
-
- Aifinyo AG
- Aixtron SE
- Berentzen Gruppe AG
- Brain Biotech AG
- Carl Zeiss Meditec AG
- Deutz AG
- Edag Engineering Group AG
- ElringKlinger AG
- Encavis AG
- Energiekontor AG
- Hypoport SE
- Jost Werke SE
- Knaus Tabbert AG
- LEG Immobilien SE
- Media and Games Invest SE
- Mister Spex SE
- Mountain Alliance AG
- Mutares SE
- Nemetschek SE
- Rational AG
- Schaltbau Holding AG
- SFC Energy AG
- Sixt SE
- Talanx AG
- USU Software AG
- Varta AG
- voxeljet AG
- Wacker Chemie AG
- Zeal Network SE
- Presentations
- Sector
- Index
- Speaker
- About
- Blog
February 24, 2022
15:21 
BRAIN Biotech AG Elevator Pitch: Key Takeaways
Discover Q1-2022 Financials and Insights from BRAIN Biotech AG
In this comprehensive video presentation, Michael Schneiders, Investor Relations, provides an in-depth look into BRAIN’s group structure, strategic deals, cutting-edge technology, and financial highlights. Learn about the Breatec deal, PHA 121, the SolasCure partnership, and the groundbreaking BEC patent. Gain insights into the long-term revenue growth trajectory and the company’s response to Covid, supply chain challenges, and inflation.
Â
Understanding BRAIN’s Guidance and Mid-Term Targets
Understand BRAIN’s guidance and mid-term targets as they continue to innovate and develop bio-based products and solutions for nutrition, health, and the environment.
Â
Exploring the BRAIN Group’s Diverse Collection and Global Presence
The BRAIN Group maintains its diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions already successfully employed in the industry. The BRAIN Group has production facilities in Germany, the UK and the US, which, together with the associated biotechnological production expertise, complete the value chain within the Group.
Â
Commitment to Global Standards and Societal Goals
As a United Nations Global Compact participant, BRAIN Biotech AG is committed to aligning strategies and operations with universal human rights, labour, environment and anti-corruption principles and taking actions that advance societal goals.
Â
Stock Market Presence Since IPO in 2016
Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE000520394
Chapters
- Introduction
- Brain at a Glance
- Brain Group Structure
- Breatec Deal Summary
- PHA 121
- SolasCure
- BEC Partnership
- BEC – Patent Published
- Genome Editing: Platform Business
- Financial Highlights
- Long-Term Revenue Growth Trajectory
- Covid, Supply Chain, Inflation
- Guidance and Mid-Term Targets
Resources
Host
Share
T&C:
This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/
Continuing the Journey: More Presentations
Discover Additional Elevator Pitches
Reviews for BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals & Growth Trajectory with IR
There are currently no reviews for BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals & Growth Trajectory with IR